All authors were involved

in at least one of the following: Selleckchem ARN-509 conception, design, data acquisition, data analysis, statistical analysis, and interpretation of data. All authors drafted the manuscript and/or revised the manuscript for important intellectual Foretinib content, and all authors provided final approval of the version to be published. Organon (now Merck & Co., Inc.) provided the study drug (Org 26576) and financial support for the conduct of the studies. Dr. Nations was employed by Merck Sharp & Dohme Corp. (Whitehouse Station, NJ, USA) at the time of this research. Drs. Bursi and Schipper were employed by Merck Sharp & Dohme Oss BV (Oss, the Netherlands) at the time of this research. Dr. Dogterom is currently an employee of Merck Sharp & Dohme Oss BV. The employers of Drs. Ereshefsky and Gertsik (California Clinical Trials Medical Group, Inc.) and Dr. Mant (Quintiles) were paid by Organon (now Merck & Co., Inc.) for their work on this trial. References 1. Cutler NR, Sramek JJ, Murphy MF, et al. Critical pathways to success in CNS drug development. 1st ed. Oxford: LY2874455 clinical trial Wiley-Blackwell, 2010CrossRef 2. Sramek JJ, Cutler NR. Investigator perspective on MTD: practical application of an MTD definition — has it accelerated development? J Clin Pharmacol 2000; 40: 1184–7.PubMed 3. Ereshefsky L, Jhee

S, Gertsik L, et al. Strategies to accelerate drug development for CNS compounds: focus on schizophrenia [poster]. 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15–18; Barcelona 4. Vanover K, Davis R, Ereshefsky L, et al. Safety, pharmacokinetics and early signals for efficacy of ITI-007, a novel investigational drug for the treatment of schizophrenia and related disorders [poster]. 13th International Congress on Schizophrenia Research; 2011 Apr 2–6; Colorado Springs (CO) 5. Cutler NJ, Sramek second JJ. Guidelines for conducting bridging studies in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1998; 12 (2): 88–92.CrossRefPubMed 6. Cutler NR, Sramek JJ, Greenblatt DJ, et al. Defining the maximum tolerated dose: investigator,

academic, industry, and regulatory perspectives. J Clin Pharmacol 1997; 37 (9): 767–83.CrossRefPubMed 7. Anand R, Geffen Y, Vasile D, et al. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perhenazine. Clin Neuropharmacol 2010; 33 (6): 297–302.CrossRefPubMed 8. Fitzgerald PB. BL-1020: an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Curr Opin Investig Drugs 2010; 11 (1): 92–100.PubMed 9. Ereshefsky L, Gage A, Yu B, et al. Phase 1 study of RGH-188 in schizophrenic patients [poster]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3–8; Washington, DC 10. Sramek JJ, Kirkesseli S, Paccaly-Moulin A, et al. A bridging study of fananserin in schizophrenic patients.